X-Linked Protoporphyria

Clinical characteristics.

X-linked protoporphyria (XLP) is characterized in affected males by cutaneous photosensitivity (usually beginning in infancy or childhood) that results in tingling, burning, pain, and itching within minutes of sun/light exposure and may be accompanied by swelling and redness. Blistering lesions are uncommon. Pain, which may seem out of proportion to the visible skin lesions, may persist for hours or days after the initial phototoxic reaction. Photosensitivity is lifelong. Multiple episodes of acute photosensitivity may lead to chronic changes of sun-exposed skin (lichenification, leathery pseudovesicles, grooving around the lips) and loss of lunulae of the nails. An unknown proportion of individuals with XLP develop liver disease. Except for those with advanced liver disease, life expectancy is not reduced. The phenotype in heterozygous females ranges from asymptomatic to as severe as in affected males.

Diagnosis/testing.

The diagnosis of XLP is established in a male proband with markedly increased free erythrocyte protoporphyrin and zinc-chelated erythrocyte protoporphyrin by identification of a hemizygous pathogenic gain-of-function variant in ALAS2 on molecular genetic testing.

The diagnosis of XLP is established in a female proband with increased free erythrocyte protoporphyrin and zinc-chelated erythrocyte protoporphyrin by identification of a heterozygous pathogenic gain-of-function variant in ALAS2 on molecular genetic testing.

Management.

Treatment of manifestations: The phototoxicity and subsequent pain can be reduced by the administration of afamelanotide, an α-melanocyte-stimulating hormone analog. Otherwise, the only effective treatment is prevention of the painful attacks by avoidance of sun/light (including the long-wave ultraviolet light that passes through window glass) through use of protective clothing (e.g., long sleeves, gloves, wide-brimmed hats, protective tinted glass for cars and windows). Although topical sunscreens are typically not useful, some tanning products containing creams that cause increased pigmentation may be helpful. Oral Lumitene™ (β-carotene) has been used to improve tolerance to sunlight by causing mild skin discoloration due to carotenemia; however, a systematic review of treatment options showed no evidence of efficacy. Vitamin D supplementation is recommended to prevent vitamin D insufficiency due to sun avoidance.

Severe liver complications are difficult to treat: cholestyramine and other porphyrin absorbents (to interrupt the enterohepatic circulation of protoporphyrin and promote its fecal excretion) and plasmapheresis and intravenous hemin are sometimes beneficial. Liver transplantation can be a lifesaving measure in individuals with severe protoporphyric liver disease; combined bone marrow and liver transplantation is indicated in those with liver failure to prevent future damage to the allografts.

Surveillance: Monitoring of: hepatic function every 6-12 months and hepatic imaging if cholelithiasis is suspected; erythrocyte protoporphyrin levels (free and zinc-chelated), hematologic indices, and iron profile annually; vitamin D 25-OH levels.

Agents/circumstances to avoid: Sunlight and UV light; for those with hepatic dysfunction, drugs that may induce cholestasis (e.g., estrogens). For those with cholestatic liver failure, protective filters should be used for the operating room lights for liver transplant surgery to avoid phototoxic damage.

Evaluation of relatives at risk: If the ALAS2 pathogenic variant has been identified in an affected family member, at-risk relatives can be tested as newborns or infants so that those with the pathogenic variant can benefit from early intervention (sun protection) and future monitoring for signs of liver dysfunction.

Genetic counseling.

By definition, XLP is inherited in an X-linked manner. Affected males transmit the pathogenic variant to all of their daughters and none of their sons. Women with an ALAS2 pathogenic variant have a 50% chance of transmitting the variant to each child. Once the ALAS2 pathogenic variant has been identified in an affected family member, heterozygote testing for at-risk female relatives, prenatal testing for pregnancies at increased risk, and preimplantation genetic testing are possible.

Suggestive Findings

X-linked protoporphyria (XLP) should be suspected in individuals with the following clinical findings and initial laboratory findings.

Clinical findings

• Cutaneous photosensitivity, usually beginning in childhood
• Burning, tingling, pain, and itching of the skin (the most common findings); may occur within minutes of sun/light exposure, followed later by erythema and swelling
• Painful symptoms; may occur without obvious skin damage
• Absent or sparse blisters and bullae
  Note: The absence of skin damage (e.g., scarring), vesicles, and bullae often make it difficult to suspect the diagnosis.
• Hepatic complications, particularly cholestatic liver disease, may develop in fewer than 5% of patients.

Initial laboratory findings. Detection of markedly increased free erythrocyte protoporphyrin and zinc-chelated erythrocyte protoporphyrin is the most sensitive biochemical diagnostic test for XLP (Table 1).

Note: It is essential to use an assay for erythrocyte protoporphyrin that distinguishes between free protoporphyrin and zinc-chelated protoporphyrin to differentiate XLP from erythropoietic protoporphyria (EPP-AR) and several other conditions that may lead to elevation of erythrocyte protoporphyrins (see Table 1, footnotes 3 and 4).

Establishing the Diagnosis

Male proband. The diagnosis of X-linked protoporphyria (XLP) is established in a male proband with markedly increased free erythrocyte protoporphyrin and zinc-chelated erythrocyte protoporphyrin by identification of a hemizygous pathogenic gain-of-function variant in ALAS2 (encoding erythroid specific 5-aminolevulinate synthase 2) on molecular genetic testing (see Table 2).

Female proband. The diagnosis of X-linked protoporphyria (XLP) is established in a female proband with increased free erythrocyte protoporphyrin and zinc-chelated erythrocyte protoporphyrin by identification of a heterozygous pathogenic gain-of-function variant in ALAS2 on molecular genetic testing (see Table 2).

Clinical Description

The natural history of X-linked protoporphyria (XLP) is not as well characterized as that of the autosomal recessive type of erythropoietic protoporphyria (EPP-AR) (see Differential Diagnosis). A natural history study from the US described 22 individuals with XLP from seven unrelated families [Balwani et al 2017].

Pathophysiology

Bone marrow reticulocytes are thought to be the primary source of the accumulated protoporphyrin that is excreted in bile and feces. Most of the excess protoporphyrin in circulating erythrocytes is found in a small percentage of cells, and the rate of protoporphyrin leakage from these cells is proportional to their protoporphyrin content.

The skin of persons with XLP is maximally sensitive to visible blue-violet light near 400 nm, which corresponds to the so-called "Soret band" (the narrow peak absorption maximum that is characteristic for protoporphyrin and other porphyrins). When porphyrins absorb light they enter an excited energy state. This energy is presumably released as fluorescence and by formation of singlet oxygen and other oxygen radicals that can produce tissue and vessel damage. This may involve lipid peroxidation, oxidation of amino acids, and cross-linking of proteins in cell membranes.

Photoactivation of the complement system and release of histamine, kinins, and chemotactic factors may mediate skin damage. Histologic changes occur predominantly in the upper dermis and include deposition of amorphous material containing immunoglobulin, complement components, glycoproteins, glycosaminoglycans, and lipids around blood vessels. Damage to capillary endothelial cells in the upper dermis has been demonstrated immediately after light exposure in this disease [Schneider-Yin et al 2000].

Long-term observations of patients with protoporphyria generally show little change in protoporphyrin levels in erythrocytes, plasma, and feces [Gou et al 2018]. In contrast, severe hepatic complications, when they occur, often follow increasing accumulation of protoporphyrin in erythrocytes, plasma, and liver. Iron deficiency and factors that impair liver function sometimes contribute. Enterohepatic circulation of protoporphyrin may favor its return and retention in the liver, especially when liver function is impaired. Liver damage probably results at least in part from protoporphyrin accumulation itself. As this porphyrin is insoluble, it tends to form crystalline structures in liver cells, can impair mitochondrial functions in liver cells, and can decrease hepatic bile formation and flow [Anderson et al 2001].

Genotype-Phenotype Correlations

Because of the limited number of families known to have XLP, no genotype-phenotype correlations have been identified.

Penetrance

XLP appears to be 100% penetrant in males.

In heterozygous females, clinical variability is attributed to random X-chromosome inactivation. Symptomatic females have been reported [Whatley et al 2008, Di Pierro et al 2009].

Nomenclature

Although sometimes considered a synonym for XLP, the term "erythropoietic protoporphyria, X-linked dominant" is incorrect and should not be used: in all X-linked metabolic disorders the phenotype in heterozygous females can range from asymptomatic to as severe as that seen in affected male relatives.

Prevalence

The prevalence of XLP is unknown.

• Based on studies from the UK, XLP appears to account for about 2% of individuals with the erythropoietic protoporphyria phenotype [Whatley et al 2010].
• In the US, XLP accounts for about 10% of individuals with the erythropoietic protoporphyria phenotype [Balwani et al 2017].

Evaluations Following Initial Diagnosis

To establish the extent of disease and needs of an individual diagnosed with X-linked protoporphyria (XLP), the evaluations summarized in this section (if not performed as part of the evaluation that led to the diagnosis) are recommended [Balwani 2019]:

• Comprehensive medical history including history of phototoxicity
• Complete physical examination, including thorough skin examination
• Assessment of erythrocyte protoporphyrin levels (free and zinc-chelated), complete blood count with indices to evaluate for anemia, and iron profile (including ferritin) to monitor iron stores
• Assessment for liver disease:
  • Hepatic function panel (including serum aminotransferases)
  • Imaging studies such as abdominal ultrasound examination if cholelithiasis is suspected
  • Newer imaging modalities such as Fibroscan^® may be useful in evaluating liver fibrosis; however, this has not been validated in erythropoietic protoporphyria, autosomal recessive (EPP-AR) or XLP.
  • A liver biopsy may be indicated to evaluate for protoporphyric liver disease.
• Vitamin D studies to evaluate for deficiency as affected individuals are predisposed to vitamin D insufficiency due to sun avoidance
• Consultation with a clinical geneticist and/or genetic counselor

Treatment of Manifestations

Acute photosensitivity. Although several treatments have been proposed, most have been tried only in a single individual or a small number of patients.

• Use of protective clothing including long sleeves, gloves, and wide-brimmed hats is indicated.
• Protective tinted glass for cars and windows prevents exposure to UV light. Gray or smoke-colored filters provide only partial protection.
• Topical sunscreens are typically not useful; however, some tanning products containing creams that cause increased pigmentation may be helpful. Sun creams containing a physical reflecting agent (e.g., zinc oxide) are often effective but are not cosmetically acceptable to all.
• Oral Lumitene™ (β-carotene) (120–180 mg/dL) has been used to improve tolerance to sunlight if the dose is adjusted to maintain serum carotene levels in the range of 10-15 μmol/L (600–800 μg/dL), causing mild skin discoloration due to carotenemia. The beneficial effects of β-carotene may involve quenching of singlet oxygen or free radicals. However, a systematic review of about 25 studies showed that the available data are unable to prove efficacy of treatments including beta-carotene, N-acetyl cysteine, and vitamin C [Minder et al 2009].
• Afamelanotide (Scenesse^®), a controlled-release, long-acting, α-melanocyte-stimulating hormone analogue, increases eumelanin by binding to the melanocortin-1 receptor and provides photoprotection by increasing pigmentation and antioxidant properties [Harms et al 2009, Minder 2010].

Afamelanotide showed positive results in Phase III clinical trials in the US and Europe [Langendonk et al 2015]. Long-term studies in Europe show good compliance, clinical effectiveness, and improved quality of life [Biolcati et al 2015]. It was approved for patients with the EPP phenotype by the European Medicines Agency in 2014, and by the FDA in October 2019.

Hepatic disease. Treatment of hepatic complications, which may be accompanied by motor neuropathy, is difficult.

• Cholestyramine and other porphyrin absorbents, such as activated charcoal, may interrupt the enterohepatic circulation of protoporphyrin and promote its fecal excretion, leading to some improvement [McCullough et al 1988].
• Plasmapheresis and intravenous hemin are sometimes beneficial [Do et al 2002].
• Liver transplantation has been performed as a lifesaving measure in individuals with severe protoporphyric liver disease [McGuire et al 2005, Wahlin et al 2011b]. However, many transplant recipients experience a recurrence of the protoporphyric liver disease in the transplanted liver. Combined bone marrow and liver transplantation is indicated in patients with liver failure to prevent future damage to the allografts [Rand et al 2006], and sequential liver and bone marrow transplantation has been successful in curing protoporphyric liver disease [Wahlin & Harper 2010].
• Bone marrow transplantation has also been attempted without liver transplantation in some instances. A child age two years with XLP and stage IV hepatic fibrosis was treated with a hematopoietic progenitor cell transplantation that stabilized his liver disease, thus avoiding liver transplantation [Butler et al 2015].

Other

• Vitamin D supplementation is advised as patients are predisposed to vitamin D insufficiency due to sun avoidance.
• Immunization for hepatitis A and B is recommended.
• Iron supplementation may be attempted in persons with XLP who have anemia and low ferritin levels.
  Whatley et al [2008] reported some evidence of diminished iron stores in males with XLP; in one patient with iron deficiency, iron repletion decreased protoporphyrin accumulation and corrected the anemia. Subsequent reports indicate that iron supplementation can improve protoporphyrin levels, liver damage, and anemia in XLP [Landefeld et al 2016]. A pilot study using oral iron supplementation in persons with XLP showed a reduction in protoporphyrin levels [Balwani 2019].

Surveillance

Agents/Circumstances to Avoid

The following are appropriate:

• Avoidance of sunlight and UV light
• In patients with hepatic dysfunction, avoidance of alcohol and drugs that may induce cholestasis (e.g., estrogens)
• In patients with cholestatic liver failure, use of protective filters for artificial lights in the operating room to prevent phototoxic damage during procedures such as endoscopy and surgery [Wahlin et al 2008]

Evaluation of Relatives at Risk

It is appropriate to clarify the genetic status of at-risk newborn or infant family members in order to identify as early as possible those who would benefit from early intervention (sun protection) and routine monitoring (Table 4).

Evaluations include:

• Targeted molecular genetic testing if the ALAS2 pathogenic variant has been identified in an affected family member;
• Detection of markedly elevated erythrocyte protoporphyrin levels with a predominance of metal-free protoporphyrin if the pathogenic variant in the family is not known.

See Genetic Counseling for issues related to testing of at-risk relatives for genetic counseling purposes.

Pregnancy Management

There is no information on pregnancy management in XLP. Based on experience with autosomal recessive EPP, pregnancy is unlikely to be complicated by XLP [Poh-Fitzpatrick 1997].

Therapies Under Investigation

A Phase II clinical trial with MT-7117, an oral small molecule that works as a melanocortin 1 receptor agonist and increases skin pigmentation, has been completed. A Phase III clinical trial for adults and children is planned for MT-7117.

Search ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for access to information on clinical studies for a wide range of diseases and conditions.